Transgenic mice expressing mutant A53T human alpha-synuclein show neuronal dysfunction in the absence of aggregate formation

Molecular and Cellular Neuroscience

Volumn 24, Issue 2, 2003, Pages 419-429

  Gispert, Suzana ^a,b   Del Turco, Domenico ^a   Garrett, Lisa ^b   Chen, Amy ^b   Bernard, David J ^b   Hamm Clement, John ^a   Korf, Horst Werner ^a   Deller, Thomas ^a   Braak, Heiko ^a   Auburger, Georg ^b,c   Nussbaum, Robert L ^b  

^a GOETHE UNIVERSITY   (Germany)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; MUTANT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIORAL SCIENCE; CONTROLLED STUDY; CORRELATION ANALYSIS; DENDRITE; GAIT; GENE EXPRESSION; GENE OVEREXPRESSION; GRIP STRENGTH; HUMAN; IMMUNOGOLD ELECTRON MICROSCOPY; MOTOR ACTIVITY; MOUSE; NERVE FIBER; NONHUMAN; PATHOGENESIS; PERIKARYON; PRIORITY JOURNAL; PROTEIN AGGREGATION; TRANSGENIC MOUSE; WILD TYPE;

ANIMALIA; MUS MUSCULUS;

EID: 10744221260     PISSN: 10447431     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1044-7431(03)00198-2     Document Type: Article

References (39)

1. Arawaka S., Saito Y., Murayama S., Mori H. Lewy body in neurodegeneration with brain iron accumulation type 1 is immunoreactive for alpha-synuclein. Neurology. 51:1998;887-889.
2. Basso D.M., Beattie M.S., Bresnahan J.C. A sensitive and reliable locomotor rating scale for open field testing in rats. J. Neurotrauma. 12:1995;1-21.
3. Braak H., Del Tredici K., Rüb U., de Vos R.A.I., Jansen Steur E.N.H., Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging. 24:2003;197-210.
4. Campbell B.C., McLean C.A., Culvenor J.G., Gai W.P., Blumbergs P.C., Jakala P., Beyreuther K., Masters C.L., Li Q.X. The solubility of alpha-synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson's disease. J. Neurochem. 76:2001;87-96.
5. Clayton D.F., George J.M. Synucleins in synaptic plasticity and neurodegenerative disorders. J. Neurosci. Res. 58:1999;120-129.
6. Conway K.A., Harper J.D., Lansbury P.T. Jr. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry. 39:2000;2552-2563.
7. Cummings C.J., Reinstein E., Sun Y., Antalffy B., Jiang Y., Ciechanover A., Orr H.T., Beaudet A.L., Zoghbi H.Y. Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice. Neuron. 24:1999;879-892.
8. Demaimay, R., Chesebro, B., Caughey, B., 2000. Inhibition of formation of protease-resistant prion protein by Trypan Blue, Sirius Red and other Congo Red analogs. Arch. Virol. Suppl. 16, 277-283.
9. Dunah A.W., Jeong H., Griffin A., Kim Y.-M., Standaert D.G., Hersch S.M., Mouradian M.M., Young A.B., Tanese N., Krainc D. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science. 296:2002;2238-2243.
10. Forno L.S. The Lewy body in Parkinson's disease. Adv. Neurol. 45:1987;35-43.
11. Galvin J.E., Lee V.M., Trojanowski J.Q. Synuclelnopathies clinical and pathological implications . Arch. Neurol. 58:2001;186-190.
12. George J.M., Jin H., Woods W.S., Clayton D.F. Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron. 15:1995;361-372.
13. Giasson B.I., Uryu K., Trojanowski J.Q., Lee V.M. Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro. J. Biol. Chem. 274:1999;7619-7622.
14. Giasson B.I., Duda J.E., Quinn S.M., Zhang B., Trojanowski J.Q., Lee V.M. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron. 34:2002;521-533.
15. Hassler R. Zur pathologie der paralysis agitans und des postenzephalitischen Parkinsonismus. J. Psychol. Neurol. 48:1938;387-476.
16. Heiser V., Scherzinger E., Boeddrich A., Nordhoff E., Lurz R., Schugardt N., Lehrach H., Wanker E.E. Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules implications for Huntington's disease therapy . Proc. Natl. Acad. Sci. USA. 97:2000;6739-6744.
17. Huynh D.P., Figueroa K., Hoang N., Pulst S.M. Nuclear localization or inclusion body formation of ataxin-2 are not necessary for SCA2 pathogenesis in mouse or human. Nat. Genet. 26:2000;44-50.
18. Kahle P.J., Neumann M., Ozmen L., Muller V., Jacobsen H., Schindzielorz A., Okochi M., Leimer U., van Der Putten H., Probst A., et al. Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha-synuclein in human and transgenic mouse brain. J. Neurosci. 20:2000;6365-6373.
19. Klement I.A., Skinner P.J., Kaytor M.D., Yi H., Hersch S.M., Clark H.B., Zoghbi H.Y., Orr H.T. Ataxin-1 nuclear localization and aggregation role in polyglutamine-induced disease in SCA1 transgenic mice . Cell. 95:1998;41-53.
20. Klockgether T., Ludtke R., Kramer B., Abele M., Burk K., Schols L., Riess O., Laccone F., Boesch S., Lopes-Cendes I., et al. The natural history of degenerative ataxia a retrospective study in 466 patients . Brain. 121:(Pt 4):1998;589-600.
21. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., Przuntek H., Epplen J.T., Schols L., Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18:1998;106-108.
22. Lee M.K., Stirling W., Xu Y., Xu X., Qui D., Mandir A.S., Dawson T.M., Copeland N.G., Jenkins N.A., Price D.L. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 → Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc. Natl. Acad. Sci. USA. 99:2002;8968-8973.
23. Marsden C.D. Slowness of movement in Parkinson's disease. Mov. Disord. 4:(Suppl 1):1989;S26-37.
24. Masliah E., Rockenstein E., Veinbergs I., Mallory M., Hashimoto M., Takeda A., Sagara Y., Sisk A., Mucke L. Dopaminergic loss and inclusion body formation in alpha-synuclein mice implications for neurodegenerative disorders . Science. 287:2000;1265-1269.
25. McLean C.A., Cherny R.A., Fraser F.W., Fuller S.J., Smith M.J., Beyreuther K., Bush A.I., Masters C.L. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 46:1999;860-866.
26. Mezey E., Dehejia A., Harta G., Papp M.I., Polymeropoulos M.H., Brownstein M.J. Alpha synuclein in neurodegenerative disorders murderer or accomplice? Nat. Med. 4:1998;755-757.
27. Murphy D.D., Rueter S.M., Trojanowski J.Q., Lee V.M. Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J. Neurosci. 20:2000;3214-3220.
28. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 276:1997;2045-2047.
29. Richfield E.K., Thiruchelvam M.J., Cory-Slechta D.A., Wuertzer C., Gainetdinov R.R., Caron M.G., Di Monte D.A., Federoff H.J. Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice. Exp. Neurol. 175:2002;35-48.
30. Saudou F., Finkbeiner S., Devys D., Greenberg M.E. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell. 95:1998;55-66.
31. Sharon R., Bar-Joseph I., Frosch M.P., Walsh D.M., Hamilton J.A., Selkoe D.J. The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron. 37:2003;583-595.
32. Shimura H., Schlossmacher M.G., Hattori N., Frosch M.P., Trockenbacher A., Schneider R., Mizuno Y., Kosik K.S., Selkoe D.J. Ubiquitination of a new form of alpha-synuclein by parkin from human brain implications for Parkinson's disease . Science. 293:2001;263-269.
33. Sisodia S.S. Nuclear inclusions in glutamine repeat disorders are they pernicious, coincidental, or beneficial? Cell. 95:1998;1-4.
34. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., Goedert M. Alpha-synuclein in Lewy bodies. Nature. 388:1997;839-840.
35. Touchman J.W., Dehejia A., Chiba-Falek O., Cabin D.E., Schwartz J.R., Orrison B.M., Polymeropoulos M.H., Nussbaum R.L. Human and mouse alpha-synuclein genes comparative genomic sequence analysis and identification of a novel gene regulatory element . Genome Res. 11:2001;78-86.
36. Ueda K., Fukushima H., Masliah E., Xia Y., Iwai A., Yoshimoto M., Otero D.A., Kondo J., Ihara Y., Saitoh T. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. USA. 90:1993;11282-11286.
37. Wakabayashi K., Hayashi S., Kakita A., Yamada M., Toyoshima Y., Yoshimoto M., Takahashi H. Accumulation of alpha-synuclein/NACP is a cytopathological feature common to Lewy body disease and multiple system atrophy. Acta Neuropathol. (Berl). 96:1998;445-452.
38. Watase K., Weeber E.J., Xu B., Antalffy B., Yuva-Paylor L., Hashimoto K., Kano M., Atkinson R., Sun Y., Armstrong D.L., et al. A long CAG repeat in the mouse Sca1 locus replicates SCA1 features and reveals the impact of protein solubility on selective neurodegeneration. Neuron. 34:2002;905-919.
39. Wilke K., Duman B., Horst J. Diagnosis of haploidy and triploidy based on measurement of gene copy number by real-time PCR. Hum. Mutat. 16:2000;431-436.